HUP0401091A2 - Atazanavir alkalmazása HIV-terápiában - Google Patents
Atazanavir alkalmazása HIV-terápiábanInfo
- Publication number
- HUP0401091A2 HUP0401091A2 HU0401091A HUP0401091A HUP0401091A2 HU P0401091 A2 HUP0401091 A2 HU P0401091A2 HU 0401091 A HU0401091 A HU 0401091A HU P0401091 A HUP0401091 A HU P0401091A HU P0401091 A2 HUP0401091 A2 HU P0401091A2
- Authority
- HU
- Hungary
- Prior art keywords
- atazanavir
- therapy
- hiv protease
- cholesterol
- hiv
- Prior art date
Links
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 title abstract 5
- 108010019625 Atazanavir Sulfate Proteins 0.000 title abstract 5
- 229960003277 atazanavir Drugs 0.000 title abstract 5
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 title abstract 5
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 2
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 2
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Az találmány szerint atazanavir (BMS-232632) alkalmazható HIV-fertőzéskezelésénél emelkedett plazma LDL-koleszterin és/vagy trigliceridszintek csökkentésére szolgáló gyógyszerkészítményekben olyanbetegeknél; akiknél egy előzetes HIV proteáz terápia következményekéntemelkedett plazma LDL-koleszterin és/vagy triglicerid szintekmutathatók ki. A terápiában az ártalmas HIV-proteáz inhibitor helyettatazanavir vagy az atazanavir és egy citokrom P450 monooxigenázzalmetabolizált HIV-proteáz inhibitor kombinációját tartalmazógyógyszerkészítmény alkalmazható. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31674501P | 2001-08-31 | 2001-08-31 | |
| PCT/US2002/026675 WO2003020206A2 (en) | 2001-08-31 | 2002-08-21 | Use of atazanavir in hiv therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0401091A2 true HUP0401091A2 (hu) | 2004-08-30 |
Family
ID=23230468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401091A HUP0401091A2 (hu) | 2001-08-31 | 2002-08-21 | Atazanavir alkalmazása HIV-terápiában |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20030045501A1 (hu) |
| EP (1) | EP1420799B1 (hu) |
| JP (1) | JP2005501880A (hu) |
| KR (1) | KR20040029447A (hu) |
| CN (1) | CN1245988C (hu) |
| AT (1) | ATE341332T1 (hu) |
| AU (1) | AU2002332610B2 (hu) |
| BG (1) | BG108585A (hu) |
| BR (1) | BR0211544A (hu) |
| CA (1) | CA2458807A1 (hu) |
| CZ (1) | CZ2004288A3 (hu) |
| DE (1) | DE60215189T2 (hu) |
| DK (1) | DK1420799T3 (hu) |
| EE (1) | EE200400065A (hu) |
| ES (1) | ES2274119T3 (hu) |
| HK (1) | HK1061640A1 (hu) |
| HR (1) | HRP20040181A2 (hu) |
| HU (1) | HUP0401091A2 (hu) |
| IL (1) | IL159849A0 (hu) |
| IS (1) | IS7158A (hu) |
| MX (1) | MXPA04001721A (hu) |
| NO (1) | NO20040803L (hu) |
| NZ (1) | NZ530722A (hu) |
| PL (1) | PL367873A1 (hu) |
| RU (1) | RU2316341C2 (hu) |
| WO (1) | WO2003020206A2 (hu) |
| YU (1) | YU12204A (hu) |
| ZA (1) | ZA200401412B (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2543596A1 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
| US20050148523A1 (en) * | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
| EP2003120B9 (en) * | 2007-06-12 | 2010-06-02 | CoNCERT Pharmaceuticals, Inc. | Azapeptide derivatives as HIV protease inhibitors |
| ES2361796T3 (es) * | 2007-06-22 | 2011-06-22 | Bristol-Myers Squibb Company | Composiciones en comprimidos que contienen atazanavir. |
| PL2170292T3 (pl) * | 2007-06-22 | 2014-06-30 | Bristol Myers Squibb Holdings Ireland | Tabletkowane kompozycje zawierające atazanawir |
| AU2008268627A1 (en) * | 2007-06-22 | 2008-12-31 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
| JP2010530890A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| NZ584968A (en) * | 2007-10-29 | 2012-11-30 | Cipla Ltd | Novel antiretroviral combination comprising ritonavir and atazanavir |
| CN101249138B (zh) * | 2008-03-28 | 2012-03-21 | 中国人民解放军军事医学科学院野战输血研究所 | 一种含五味子乙醇提取物的抗艾滋病药物组合物 |
| CN102905698A (zh) * | 2010-04-02 | 2013-01-30 | 菲弗科－1有限责任公司 | 包含ccr5拮抗剂、hiv-1蛋白酶抑制剂和药代动力学增强剂的组合疗法 |
-
2002
- 2002-08-21 CA CA002458807A patent/CA2458807A1/en not_active Abandoned
- 2002-08-21 JP JP2003524520A patent/JP2005501880A/ja not_active Withdrawn
- 2002-08-21 PL PL02367873A patent/PL367873A1/xx not_active Application Discontinuation
- 2002-08-21 KR KR10-2004-7002851A patent/KR20040029447A/ko not_active Application Discontinuation
- 2002-08-21 DK DK02797744T patent/DK1420799T3/da active
- 2002-08-21 WO PCT/US2002/026675 patent/WO2003020206A2/en active IP Right Grant
- 2002-08-21 CZ CZ2004288A patent/CZ2004288A3/cs unknown
- 2002-08-21 MX MXPA04001721A patent/MXPA04001721A/es active IP Right Grant
- 2002-08-21 US US10/225,754 patent/US20030045501A1/en not_active Abandoned
- 2002-08-21 RU RU2004106787/14A patent/RU2316341C2/ru not_active IP Right Cessation
- 2002-08-21 AT AT02797744T patent/ATE341332T1/de not_active IP Right Cessation
- 2002-08-21 CN CNB028166868A patent/CN1245988C/zh not_active Expired - Fee Related
- 2002-08-21 EE EEP200400065A patent/EE200400065A/xx unknown
- 2002-08-21 NZ NZ530722A patent/NZ530722A/en unknown
- 2002-08-21 IL IL15984902A patent/IL159849A0/xx unknown
- 2002-08-21 HU HU0401091A patent/HUP0401091A2/hu unknown
- 2002-08-21 BR BR0211544-1A patent/BR0211544A/pt not_active IP Right Cessation
- 2002-08-21 EP EP02797744A patent/EP1420799B1/en not_active Expired - Lifetime
- 2002-08-21 ES ES02797744T patent/ES2274119T3/es not_active Expired - Lifetime
- 2002-08-21 AU AU2002332610A patent/AU2002332610B2/en not_active Ceased
- 2002-08-21 DE DE60215189T patent/DE60215189T2/de not_active Expired - Fee Related
- 2002-08-21 YU YU12204A patent/YU12204A/sh unknown
-
2004
- 2004-02-17 BG BG108585A patent/BG108585A/bg unknown
- 2004-02-19 IS IS7158A patent/IS7158A/is unknown
- 2004-02-20 ZA ZA200401412A patent/ZA200401412B/en unknown
- 2004-02-23 HR HR20040181A patent/HRP20040181A2/xx not_active Application Discontinuation
- 2004-02-24 NO NO20040803A patent/NO20040803L/no not_active Application Discontinuation
- 2004-06-24 HK HK04104527A patent/HK1061640A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0211544A (pt) | 2004-07-13 |
| RU2316341C2 (ru) | 2008-02-10 |
| MXPA04001721A (es) | 2004-05-31 |
| DE60215189T2 (de) | 2007-10-25 |
| EE200400065A (et) | 2004-06-15 |
| DE60215189D1 (de) | 2006-11-16 |
| HRP20040181A2 (en) | 2004-08-31 |
| JP2005501880A (ja) | 2005-01-20 |
| CZ2004288A3 (cs) | 2004-12-15 |
| NO20040803L (no) | 2004-02-24 |
| DK1420799T3 (da) | 2007-01-15 |
| CN1547476A (zh) | 2004-11-17 |
| ZA200401412B (en) | 2005-03-18 |
| ATE341332T1 (de) | 2006-10-15 |
| AU2002332610B2 (en) | 2007-11-08 |
| IL159849A0 (en) | 2004-06-20 |
| KR20040029447A (ko) | 2004-04-06 |
| WO2003020206A2 (en) | 2003-03-13 |
| US20030045501A1 (en) | 2003-03-06 |
| EP1420799A4 (en) | 2004-11-24 |
| ES2274119T3 (es) | 2007-05-16 |
| EP1420799A2 (en) | 2004-05-26 |
| CN1245988C (zh) | 2006-03-22 |
| EP1420799B1 (en) | 2006-10-04 |
| IS7158A (is) | 2004-02-19 |
| HK1061640A1 (en) | 2004-09-30 |
| PL367873A1 (en) | 2005-03-07 |
| BG108585A (bg) | 2005-04-30 |
| WO2003020206A3 (en) | 2003-10-02 |
| YU12204A (sh) | 2006-08-17 |
| CA2458807A1 (en) | 2003-03-13 |
| NZ530722A (en) | 2007-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011671A (es) | Vacunas contra el coronavirus y metodos de uso. | |
| CY1110604T1 (el) | Συνδυασμος αναστολεων πρωτεασης που εξαρτωνται απο το κυτοχρωμα ρ450 | |
| UA89220C2 (ru) | Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы | |
| NO20063958L (no) | HIV integrase inhibitorer | |
| IL175211A0 (en) | Pharmaceutical compositions and kits containing a hepatitis c virus ns3/4a protease inhibitor and cytochrome p450 monooxygenase inhibitor | |
| ATE508735T1 (de) | Pulmonale verabreichung von aminoglykosiden | |
| EA200401525A1 (ru) | Способы лечения гепатита (варианты ) | |
| NO20034094L (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
| HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
| NO20053455L (no) | Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer | |
| HUP0401091A2 (hu) | Atazanavir alkalmazása HIV-terápiában | |
| DK1259240T3 (da) | Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme | |
| TW200738700A (en) | HIV integrase inhibitors | |
| NO20090322L (no) | 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor | |
| HUP0203295A2 (hu) | Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával | |
| WO2007002172A3 (en) | Hiv-1 protease inhibitors | |
| WO2004101512A3 (en) | Naphthyridine integrase inhibitors | |
| HUP0202638A2 (hu) | Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására | |
| MX2023009527A (es) | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. | |
| EP1696918A4 (en) | METHOD FOR THE TREATMENT OF HIV INFECTIONS IN PATIENTS WITH ATAZANAVIR RESISTANCE USING A COMBINATION OF ATAZANAVIR AND ANOTHER PROTEASE INHIBITOR | |
| HUP9904408A2 (hu) | Lactobacillus vakcina prosztatagyulladás és jóindulatú prostatahyperplasia kezelésére | |
| NO20050445L (no) | Synergistisk interaksjon mellom abacavir og alovudin | |
| DE50112512D1 (de) | Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel | |
| HUP0303423A2 (hu) | HIV elleni természetes ellenanyag | |
| HUP0300682A2 (hu) | Dalfopristin/kinupristin kombinációit cefpirommal együtt tartalmazó gyógyszerkészítmények |